Stocks Health care KPTI
NASDAQ · Health careKaryopharm Therapeutics Inc. (KPTI)
Karyopharm Therapeutics Inc. brought in $146.6M of revenue over the twelve months to June 30, 2026, up 6.8% from a year earlier. It posted a net loss of $224.7M. In fiscal 2025 capital spending exceeded operating cash flow by $75.4M. At June 30, 2026 it held $55M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 13, 2026.
Key facts about Karyopharm Therapeutics Inc.
- Net worth
- Karyopharm Therapeutics Inc. has a market value (market cap) of $907.3K at the latest share price, and shareholders' equity of -$330.2M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $146.1M (+0.6% year on year), with a net loss of $196M. Over the 12 months to June 30, 2026: revenue $146.6M, net loss $224.7M.
- Cash flow
- In fiscal 2025 operations used $75.4M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on August 13, 2026 and covers the period to June 30, 2026. Open on SEC EDGAR
What Karyopharm Therapeutics Inc. does
Karyopharm Therapeutics Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker KPTI.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $146.1M | -$196M | -$17.93 | -$75.4M |
| 2024 | $145.2M | -$76.4M | -$14.00 | -$127.6M |
| 2023 | $146M | -$143.1M | -$18.79 | -$92.7M |
| 2022 | $157.1M | -$165.3M | -$30.36 | -$149.7M |
| 2021 | $209.8M | -$124.1M | -$24.80 | -$107.3M |
| 2020 | $108.1M | -$196.3M | -$40.89 | -$160.4M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where KPTI ranks in Health care
Latest SEC filings
What Karyopharm Therapeutics Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- September 25, 2026Passive stake changed SCHEDULE 13G/A
- September 25, 2026Passive stake changed SCHEDULE 13G/A
- September 18, 2026
- September 11, 2026
- September 4, 2026Passive stake (5% or more) SCHEDULE 13G
- August 31, 2026Other event 8-K
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 13, 2026Quarterly report 10-Q · period to June 30, 2026Revenue fell 12% to $33.4M versus the same quarter last year; diluted EPS -$2.32 versus -$4.32.
- August 13, 2026
Insider trades
What the people running Karyopharm Therapeutics Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders sold $488.2 worth of shares in the last 90 days and bought none on the open market.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| October 1, 2026 | Abate KristinChief Accounting Officer | Sold | 378 | $449.8 |
| September 1, 2026 | Abate KristinChief Accounting Officer | Sold | 19 | $38.4 |
| July 28, 2026 | Poulton StuartEVP, Chief Development Officer | Sold | 189 | $1.3K |
| May 21, 2026 | Bohlin Garen GDirector | Received as pay | 15,508 | - |
| May 21, 2026 | Pakianathan DeepikaDirector | Received as pay | 15,508 | - |
| May 21, 2026 | Greene Barry EDirector | Received as pay | 15,508 | - |
| May 21, 2026 | Schor ChenDirector | Received as pay | 15,508 | - |
| May 21, 2026 | Oliger Christy J.Director | Received as pay | 15,508 | - |
Who owns KPTI
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| RA Capital Management, L.P.13G, passive with 3 related filers | 9.9% | August 14, 2026 |
| Affinity Asset Advisors, LLC13G, passive with 1 related filers | 8.6% | May 14, 2026 |
| Adage Capital Management, L.P.13G, passive with 2 related filers | 6.78% | August 12, 2026 |
| T. Rowe Price Investment Management, Inc.13G, passive | 6.6% | June 5, 2026 |
| Anders Hove13G, passive with 4 related filers | 5.7% | September 25, 2026 |
| Integrated Core Strategies (US) LLC13G, passive with 3 related filers | 5.7% | September 4, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 97 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| RA Capital Management, L.P. | 1,917,354 | 0 |
| Adage Capital Partners GP, L.L.C. | 1,521,322 | -285,000 |
| Acorn Capital Advisors, LLC | 1,518,113 | +1,230,287 |
| Goldman Sachs Group Inc | 1,424,658 | +477,079 |
| BlackRock, Inc. | 1,418,799 | +1,173,900 |
| Kalehua Capital Management LLC | 1,371,288 | new |
| Vanguard Capital Management LLC | 958,979 | +219,234 |
| Catalio Capital Management, LP | 940,855 | +43,146 |
| Avidity Partners Management LP | 924,487 | -2,995 |
| Two Sigma Investments, LP | 695,264 | +544,032 |
| NEA Management Company, LLC | 576,780 | new |
| Geode Capital Management, LLC | 531,231 | +325,098 |
| Ghisallo Capital Management LLC | 500,000 | new |
| Soleus Capital Management, L.P. | 440,000 | 0 |
| UBS Group AG | 353,545 | +159,528 |
| State Street Corp | 325,991 | +245,249 |
| Affinity Asset Advisors, LLC | 312,500 | -187,500 |
| Brevan Howard Capital Management LP | 309,817 | +97,450 |
| Millennium Management LLC | 305,676 | -114,895 |
| Boxer Capital Management, LLC | 302,536 | 0 |
Insiders
13 insiders reported holding 829,019 shares in total, about $33.2K at the last price.
| Holder | Shares |
|---|---|
| Paulson Richard A.President and CEO, Director | 269,747 |
| Cheng Sohanya RoshanEVP & Chief Commercial Officer | 107,940 |
| Poulton StuartEVP, Chief Development Officer | 94,632 |
| Mano MichaelEVP, CLO&Secretary | 94,398 |
| Macomber LoriEVP, CFO & Treasurer | 85,105 |
| Rangwala ReshmaEVP & Chief Medical Officer | 56,829 |
| Abate KristinChief Accounting Officer | 23,404 |
| Bohlin Garen GDirector | 18,517 |
| Greene Barry EDirector | 16,415 |
| Oliger Christy J.Director | 15,508 |
Questions about KPTI
What does Karyopharm Therapeutics Inc. do?
Karyopharm Therapeutics Inc. is a company in the Health care sector, listed on NASDAQ as KPTI. Its shares trade on NASDAQ under the ticker KPTI.
What is Karyopharm Therapeutics Inc.'s net worth?
Karyopharm Therapeutics Inc. has a market value (market cap) of $907.3K at the latest share price, and shareholders' equity of -$330.2M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Karyopharm Therapeutics Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $224.7M on revenue of $146.6M.
How much revenue does Karyopharm Therapeutics Inc. make?
Over the twelve months to June 30, 2026 Karyopharm Therapeutics Inc. reported revenue of $146.6M. That is 6.8% more than a year earlier.
When did Karyopharm Therapeutics Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 13, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the insider trade from October 2, 2026.
Similar companies
Compare KPTI with
Follow KPTI
Get an email when Karyopharm Therapeutics Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Karyopharm Therapeutics Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.